Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 6/20 | 0.48 |
| ▸ | KDM1A | O60341 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 6/20 | 0.45 |
| ▸ | HTR7 | P34969 | 6/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13633425 | 0.92 | LTA4H (0.48) | LTA4HKDM1APOLBHTR1AHTR7 | |
| SCHEMBL13633479 | 0.89 | KCNA5 (0.47) | LTA4HKDM1APOLBHTR1AHTR7 | |
| SCHEMBL13633466 | 0.88 | HTR1A (0.49) | LTA4HKDM1APOLBHTR1AHTR7 | |
| SCHEMBL14232766 | 0.86 | FLT3 (0.47) | LTA4HKDM1A | |
| SCHEMBL13633486 | 0.84 | KCNA5 (0.51) | LTA4HHTR1AHTR7KCNA5DRD2 | |
| SCHEMBL13633489 | 0.82 | HTR1A (0.46) | LTA4HKDM1APOLBHTR1AHTR7 | |
| SCHEMBL13633474 | 0.77 | HTR1A (0.54) | LTA4HKDM1AHTR1AHTR7DRD2 | |
| SCHEMBL14232441 | 0.76 | DRD4 (0.48) | LTA4H | |
| SCHEMBL13633427 | 0.75 | HTR1A (0.45) | LTA4HKDM1AHTR1AHTR7DRD2 | |
| SCHEMBL14232438 | 0.75 | DRD4 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281099-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | ANDRES-GIL JOSE IGNACIO | 2009-11-12 | — | — | US | disclosed |
| US-20090281099-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | ANDRES-GIL JOSE IGNACIO | 2009-11-12 | — | — | US | disclosed |
| WO-2007135131-A9 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA NV (BE) | 2008-04-03 | — | — | WO | disclosed |
| WO-2007135131-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281099-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | ADRA2C, CHRNA5, ADRB2 | LTA4H 3639/4885KDM1A 3474/4885POLB 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.